Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology

Similar documents
Case 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:

Introduction. Results. Discussion. Histopathologic and immunohistochemical findings. Results. conclusions,

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

The clinically challenging entity of liver metastasis from tumors of unknown primary

Differential diagnosis of HCC

- Selected Tumors of the Skin Appendages - Primary vs. Metastasis

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

BSD 2015 Case 19. Female 21. Nodule on forehead. The best diagnosis is:

Carcinoma of Unknown Primary (CUP)

Research Article A Clinicopathological and Immunohistochemical Correlation in Cutaneous Metastases from Internal Malignancies: A Five-Year Study

Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma?

Reporting of carcinoma of unknown primary tumour (CUP)

What I Learned from 3 Cases and 3 Antibodies

Histopathological diagnosis of CUP

CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY

Disclosure of Relevant Financial Relationships

Case Hx. Mrs. CP 69 female non smoker Presented with 20 lb weight loss Some changes in bowel habit but no bleeding Upper abdominal discomfort PMH

I. Diagnosis of the cancer type in CUP

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

confusing, especially in small, limited biopsies. One such case of digital papillary adnexal adenocarcinoma with unusual histologic features will be

PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

Liver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle

Carcinoma of unknown primary origin (CUP) is defined

NICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin)

Pathology Mystery and Surprise

New Developments in Immunohistochemistry for Gynecologic Pathology

Radiology Pathology Conference

Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

Radiology Pathology Conference

Unknown Slides Conference

Financial disclosures

Cutaneous metastases from gastric adenocarcinoma 15 years after curative gastrectomy *

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016

NEW IHC A n t i b o d i e s

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

List of Available TMAs in the PRN

A Cutaneous Facial Mass Identified as the New Entity Mammary Analogue Secretory Carcinoma of Probable Salivary Gland Origin

FNA Cytology of Metastatic Malignancies of Unknown Primary Site

TEST MENU BY SPECIALTY

NEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Basal cell carcinoma 5/28/2011

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

BAP-oma & BEYOND MICHAEL A NOWAK, MD

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms

NICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin)

Slide seminar. Asist. Prof. Jože Pižem, MD, PhD Institute of Pathology Medical Faculty, University of Ljubljana

Importancia del patólogo en los tumores de origen desconocido

Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources

SEBACEOUS NEOPLASMS. Dr. Prachi Saraogi Clinical Fellow in Dermatology

Case history: Figure 1. H&E, 5x. Figure 2. H&E, 20x.

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

ISSN X (Print) Original Research Article. DOI: /sjams

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Case 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset

Unusual Presentation Of A Rare Tumor: Umbilical Metastasis (Sister Mary Joseph's Nodule) Of Malignant Peritoneal Mesothelioma

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Case 4 Diagnosis 2/21/2011 TGB

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Diagnostic IHC in lung and pleura pathology

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix

Benign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more

Serous effusion Objectives. Cytology of Serous Effusions From basics to challenges

Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami

Disorders of Cell Growth & Neoplasia. Histopathology Lab

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

FNA Cytology of Metastatic Malignancies of Unknown Primary Site

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Update on Cutaneous Mesenchymal Tumors. Thomas Brenn

Fast, automated, precise

Acantholytic Anaplastic Extramammary Paget s Disease: A Case Report and Review of the Literature

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

IHC Panels as an Aid in Diagnostic Decision Making

C.L. Davis Foundation Descriptive Veterinary Pathology Course

Nordic Immunohistochemical Quality Control

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

FORELIMB SWEAT GLAND ADENOCARCINOMA IN A CAT

3/28/2017. Disclosure of Relevant Financial Relationships. Clinical History. Pathology

South East England General Histopathology EQA Scheme

Immunohistochemistry and Bladder Tumours

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors

Neoplasms of the Canine, Feline and Lemur Liver:

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

59 yo male with past medical history of prostate carcinoma, presented with upper abdominal pain

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Thyroid pathology Practical part

Epidemiology in Texas 2006 Annual Report. Cancer

Cytokeratin 20 negative Merkel cell carcinoma consistent with negative Merkel cell polyomavirus

Financial disclosures

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships

Small (and large) Blue Cell Tumors of the Skull Base

Transcription:

Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology

DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential Dermatopathology: What You Need to Know for Clinical Practice: Neoplastic DISCLOSURES I do not have any relevant relationships with industry.

Introduction Cutaneous metastases are uncommonly encountered and present a diagnostic challenge for clinicians and pathologists alike They may not be suspected and can clinically and histopathologically mimic other entities Communication with the submitting clinician is often necessary to obtain relevant clinical history as this is a big diagnosis Histopathologic and immunohistochemical results can be helpful in suggesting a primary source, but further work up is always necessary

General principles (Clinical) The overall incidence of cutaneous metastasis from a variety of internal malignancies is about 2-12% Rarely (< 1%) is skin metastasis the presenting sign of internal malignancy Poor prognosis; mean survival following a cutaneous metastasis is 7.5 months By definition these are all late stage patients

General principles (Clinical) In adults the most common primary sources are: Breast CA, melanoma, head and neck SCC, lung CA, colorectal CA, renal CA In women, most common primary sources are: Breast (69%), large intestine (9%), melanoma (5%) and ovary (4%) In men, most common primary sources are: Lung (24%), large intestine (19%), melanoma (13%), squamous cell CA of oral cavity (12%), kidney (6%) In neonates the most common sources are neuroblastoma and less commonly rhabdomyosarcoma

Clinical presentation Most common is solitary or small grouped nodule(s), firm, often rapidly growing Erythematous patch (inflammatory carcinoma, carcinoma erysipeloides) Firm indurated plaque (carcinoma en cuirasse) Grouped hemorrhagic papules (carcinoma telangiectoides)

General principles (Clinical) Often localize to same general vicinity as primary malignancy: Lung primary: Chest wall and proximal upper extremities GI and GU primaries: Abdominal wall Oral cavity and esophageal primaries: Head and neck Bladder and prostate: Abdominal wall or penis Sometimes develop at site of scars from prior surgeries, prior procedures (thoracentesis, paracentesis) and colostomy sites Scalp metastases are usually from breast, lung, or renal primaries

Sister Mary Joseph Nodule (umbilical met) Most often metastatic adenoca from stomach, large bowel, and less often ovary, pancreas, urinary bladder, endometrium

Histopathologic patterns Large nodular aggregate(s) centered in the dermis, without connection to the overlying epidermis; rare epidermotropic met seen with melanoma, prostate, and some squamous cell CA s Small nests, strands, or single cells arranged interstitially between collagen bundles; sometimes in a single file pattern (especially for breast CA) Lymphatic and vascular invasion

Distinguishing between a cutaneous metastatic adenoca and a primary skin (adnexal) neoplasm Metastatic AdenoCA Adnexal neoplasm p63 - + p40 - + D2-40 (podoplanin) - + CK 5/6 - + Exception is mucinous eccrine CA of skin which is typically p63 negative Plaza, et al: JCP 37:403,2010 Liang, et al: AJSP 31:304,2007

Cytokeratin-7 (CK7) and cytokeratin-20 (CK20) expression profiles Breast Lung (SCC) Lung (nonsmall cell) Lung (small cell) Colon/ Rectal Gastric Pancrea s/biliary Bladder/ Urotheli al Renal Ovary CK7 + + + + + + CK20 /+ + + + + Reference: Applied Immunohistochemistry 3:99-107, 1995.

Breast (Mammary) Small nests, strands, or single neoplastic cells arranged interstitially between collagen bundles, often in a single file pattern

Breast (Mammary) Neoplastic cells filling lymph-vascular spaces; Inflammatory CA ; carcinoma erysipeloides

D2-40

Breast (Mammary) Small nests and strands of neoplastic cells with surrounding desmoplasia and fibrosis; carcinoma en cuirasse

Breast (Mammary) Scalp hair follicles overrun by nests of poorly differentiated breast CA; alopecia neoplastica

Breast (Mammary) Cytokeratin-7 Positive and Cytokeratin-20 Negative (CK7+/CK20 ) CAM5.2 + (low molecular weight cytokeratin) CEA + GCDFP-15 + (Gross cystic disease fluid protein) Mammaglobin + ER and PR variably + (NOT useful as a breast marker) Rarely S100 + with melanin pigment (mimic of melanoma)

Lung Squamous cell CA CK7 /CK20 CK5/6+ Non-small cell adenocarcinoma CK7 +/CK20 TTF-1 + Small cell adenocarcinoma CK7 /CK20 (usually) TTF-1 +

Lung (small cell oat cell carcinoma) Small round blue cells Salt and pepper chromatin Fragile cells with crush artifact DDx is with primary cutaneous neuroendocrine CA (Merkel Cell CA) Merkel cell Met Small Cell CK20 + /+ TTF-1 +

Colon AdenoCA with dirty necrosis CK7 /CK20 + CEA + CDX2 + Villin +

Renal Nodular aggregates of clear cells Richly vascular CK7 /CK20 EMA + CD10+ RCC-ma + PAX8 + PAX2 + **PAX8 and PAX2 are also + in ovarian and other gyn tumors

Melanoma Nodular or nested aggregates May lose ability to produce melanin pigment S100 + Melan-A + MITF + HMB-45 +/ Some met melanomas may lose all melanocytic markers Ref: AJSP 40:181-191, 2016

Immunohistochemical stains for less common cutaneous mets Ovarian Prostate Gastric Pancreatic Bladder/Urothelial Thyroid CK7+/CK20, CA-125, WT-1 (serous), PAX8, PAX2 PSA, PSAP CK7+/CK20+, CDX2 CK7+/CK20+, CA19.9, CA125 CK7+/CK20+, p63, CK5/6 TTF-1+, thyroglobulin, calcitonin (medullary)

References Wang NP, et al: Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Applied Immunohistochemistry 3:99-107, 1995. Alcaraz I, et al: Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. American Journal of Dermatopathology 34: 347-93, 2012. Plaza JA, et al: Value of p63 and podoplanin (D2-40) in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin. Journal of Cutaneous Pathology 37:403-10, 2010. Liang, et al: Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to the skin. American Journal of Surgical Pathology 31:304-10, 2007. Agaimy A, et al: Metastatic malignant melanoma with complete loss of differentiation markers. American Journal of Surgical Pathology 40:181-91, 2016. Lee JJ, et al: p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases. Human Pathology 45(5):1078-83. 2014.